Form D · Biotechnology

Kerecis hf

Reykjavik, K6 · CIK 0001726919

Offering snapshot reported Aug 23, 2022 · SEC filing

Reported sold
$1.76M
Offering amount: $1.76M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 15, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 23, 2022Initial$1,759,734No comparison8SEC filing
Jul 1, 2020Initial$109,567No comparison4SEC filing
May 17, 2019Amendment$4,107,527$4,052,747vs May 14, 20196SEC filing
May 14, 2019Initial$54,780No comparison4SEC filing
May 24, 2018Initial$1,500,000No comparison1SEC filing
Jan 3, 2018Initial$111,582No comparison15SEC filing

Offering details

Securities
Equity, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-456783
Total offering amount and total amount sold include the conversion of convertible promissory notes

Source: Form D, filed Aug 23, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Olafur Ragnar Grimsson Director
Hilmar Janusson Director
J Ernest Kenney Director
Eric Maillard Director
Gudmundur Fertram Sigurjonsson Director, Executive
Franck Sinabian Director
Niklas Sjoblom Director
Andri Sveinsson Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Laugavegur 77 Fifth Floor
Reykjavik, K6, 101